Table 30Characteristics of placebo-controlled trials of SSRIs excluded from main analyses because of high risk of bias

StudyArm Dose mg/day (N)Duration (Weeks)Population Trauma TypeBaseline PTSD SeverityaMean Age (Y)% F% Non-whiteRisk of Bias
Hertzberg et al., 2000171Fluoxetine (10 to 60) (6)
Placebo (6)
12Male
Combat veterans
DTS
106 to 111
46058High
Marshall et al., 2007172Paroxetine (10 to 60) (25)
Placebo (27)
10Male and female
Mixed
82.8 to 84.2406775High

CAPS = Clinician Administered PTSD Scale; DTS = Davidson Trauma Scale; F = female; mg = milligram; N = total number randomized/assigned to intervention and control groups; PTSD = posttraumatic stress disorder; y = year

a

Data reported are mean CAPS or range of mean CAPS scores across groups unless another instrument is specified.

Note: When mean data for baseline PTSD severity were not reported for the total sample but were presented for each study arm, we provide the range across arms.

Data reported are mean CAPS or range of mean CAPS scores across groups unless another instrument is specified.

From: Results

Cover of Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD)
Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD) [Internet].
Comparative Effectiveness Reviews, No. 92.
Jonas DE, Cusack K, Forneris CA, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.